Cancer de la prostate

  • L. Mourey
  • J. -P. Droz

Résumé

L’adénocarcinome de prostate est un cancer extrêmement fréquent qui touche en particulier l’homme âgé. Il est en effet, le premier cancer de l’homme de plus de 70 ans en incidence mais le second pour la mortalité, après le cancer du poumon.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    D’Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 2003;21(11):2163–2172.CrossRefGoogle Scholar
  2. 2.
    Tewari A, Johnson CC, Divine G et al. Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities. J Urol 2004;171(4):1513–1519.PubMedCrossRefGoogle Scholar
  3. 3.
    Wong YN, Mitra N, Hudes G et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA 2006;296(22):2683–2693.PubMedCrossRefGoogle Scholar
  4. 4.
    Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997;157(2):439–444.PubMedCrossRefGoogle Scholar
  5. 5.
    NCCN prostate cancer guidelines. http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf. 2008. Ref Type: Internet Communication
  6. 6.
    Berthold DR, Pond GR, Soban F, de WR, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26(2):242–245.PubMedCrossRefGoogle Scholar
  7. 7.
    Italiano A, Ortholan C, Oudard S et al. Docetaxel-Based Chemotherapy in Elderly Patients (Age 75 and Older) with Castration-Resistant Prostate Cancer. Eur Urol 2008.Google Scholar
  8. 8.
    SIOG prostate cancer guidelines. http://www.cancerworld.org/CancerWorld/getStaticModFile.aspx?id=2408. 2008. Ref Type: Internet Communication
  9. 9.
    Droz JP, Chaladaj A. Management of metastatic prostate cancer: the crucial role of geriatric assessment. BJU Int 2008;101Suppl 2:23–29.PubMedCrossRefGoogle Scholar
  10. 10.
    Schroder FH, Hugosson J, Roobol MJ et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360(13):1320–1328.PubMedCrossRefGoogle Scholar
  11. 11.
    Andriole GL, Grubb RL, III, Buys SS et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360(13):1310–1319.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag France 2011

Authors and Affiliations

  • L. Mourey
    • 1
    • 3
  • J. -P. Droz
    • 2
  1. 1.Département d’Oncologie MédicaleInstitut Claudius RegaudToulouseFrance
  2. 2.Centre Léon-Bérard, Projet PROLOGUniversité Claude-Bernard-Lyon 1LyonFrance
  3. 3.Département d’Oncologie MédicaleInstitut Claudius RegaudToulouse Cedex

Personalised recommendations